Background: Despite recent advances, there is still a major need for prediction of treatment success in schizophrenia. Cortical thickness measures are relatively easy to obtain and may provide biomarker candidates. Here, we tested a set of candidate brain regions as predictors of treatment response in first episode schizophrenia and in two independent schizophrenia cohorts. Regions included the precuneus, inferior parietal gyrus, superior temporal gyrus, parahippocampal gyrus, anterior cingulate, inferior frontal gyrus, insula, lateral and medial orbitofrontal cortex, and occipital cortex. Methods: In the discovery cohort, we used the whole sample of patients to estimate individual response slopes using Empirical Bayes, 36 of which had cortical thickness measurements at baseline. Patients were scanned aprior to treatment with either risperidone or aripiprazole. Symptoms were assessed with the Brief Psychiatric Rating Scale at baseline and over the course of up to 52 weeks. Cortical thickness in regions of interest were examined via magnetic resonance imaging and used as predictors of individual treatment response, defined as individual response slope. Results: Parahippocampal thickness at baseline predicted the individual response to treatment (P < 0.05, Bonferroni-corrected). This was replicated in two independent schizophrenia cohorts including a recent onset cohort (N = 33) and a sample of chronic schizophrenia patients (N = 52), respectively. The overall effect was quantified with an internal meta-analysis (β = 0.4, 95% CI [0.24; 0.56]; z = 4.84, P < 0.001). Discussion: Parahippocampal thickness may be a promising marker of treatment success both at the early and the chronic stage of schizophrenia.
S21. EVENT-RELATED REPETITIVE TMS TO RIGHT POSTERIOR STS (BUT NOT OCCIPITAL FACE AREA) IN HEALTHY VOLUNTEERS (HV) BRIEFLY RECAPITULATES FACE EMOTION RECOGNITION (FER) DEFICITS OF SCHIZOPHRENIA (SZ)
Columbia University, Nathan Kline Institute Background: Profound FER deficits exist in Sz, causing social disability, though can be partly remediated with computer-based training. Neurostimulation might augment remediation if critical nodes were identified. We aimed to 1) briefly recapitulate FER deficits of Sz in HV using rTMS to rpSTS, 2) identify connectivity patterns of rpSTS regressed by FER, and 3) apply TMS to rpSTS with fMRI as readout. Methods: 1) Nine healthy volunteers had rTMS (10 Hz; 500 msec; 110% RMT) to rpSTS or rOFA (counterbalanced; 10/10 system overlay with standard MRI) concurrent (1/3 trials) with stimuli (http://faces.mpdl.mpg. de/) for emotion or gender identification (button press). 14 Sz patients completed these tasks without TMS. 2) Whole-brain resting-connectivity analyses, seeded by rpSTS, was applied in 27 Sz and 35 HV who also completed the UPenn FER task. 3) BOLD fMRI was obtained in 4 HV pre-and post-TMS to rpSTS (1 Hz; 20 minutes). Results: 1) In HV, rTMS to rpSTS only (not OFA) significantly slowed reaction time for FER only (not gender identification): overall F test for logRT (p=.001) with post-hoc rpSTS vs.OFA (p=.005) and rpSTS vs. non-stim trials (p=.004). rpSTS recapitulated slowed RT ad lower FER accuracy of Sz. 2) In both HV and Sz, rpSTS had significant resting connectivity with V1 (p= .00013), positively modulated by FER accuracy. 3) Analyses are ongoing. Discussion: rpSTS is a critical node in the FER circuit with connectivity to primary visual cortex modulated by FER, whose disruption recapitulates FER deficits, making it a candidate target for remediatory neurostimulation. Background: Despite an increasing research and clinical focus on transdiagnostic approaches to mental health, it remains unclear whether different diagnostic categories share a common neuronatomical basis. The current investigation sought to investigate whether a shared (trans-diagnostic) set of structural alterations characterized schizophrenia, depression, post-traumatic stress disorder and obsessive-compulsive disorder, and determine whether any such alterations reflected markers of psychiatric illness or pre-existing familial vulnerability. Methods: A total of 404 patients with a psychiatric diagnosis were recruited (psychosis, n=129; unipolar depression, n=92; post-traumatic stress disorder, n=91; obsessive compulsive disorder, n=92) alongside 201 healthy controls and 20 unaffected first-degree relatives. We collected structural Magnetic Resonance Imaging scans from each participant using the same 3.0 Tesla scanner and acquisition sequence, and tested for trans-diagnostic alterations using Voxel-Based Morphometry. Results: We report that the four psychiatric groups were all characterized by significantly greater gray matter volume in the bilateral putamen relative to healthy controls (right putamen: x=32 y=6 z=-2; z-score: 5.97; p-value<0.001 after FWE-correction; left putamen: x=-30 y=5 z=-7; z-score: 4.97; p-value=0.001 after FWE-correction). Furthermore, the volume of this region was positively correlated with severity of symptoms across groups, so that a higher gray matter volume in the putamen was associated with higher severity of symptoms (partial correlation: the results are age and gender corrected; right putamen: r=0.313, p<0.001; left putamen: =0.326, p<0.001). Bilateral putamen enlargement was also evident in unaffected relatives compared to healthy controls (right putamen: x=32 y=-6 z=2; t-value: 8.13, p-value<0.001 after FWE-correction; left putamen: x=-32 y=-8 z=2; z-score:9.39, p-value<0.001 after FWE-correction). Discussion: These findings indicate that increased putamen volume may reflect a trans-diagnostic marker of underlying familial vulnerability to psychopathology. This raises the prospect that this region could be used to assess degree of familiar vulnerability to psychopathology above and beyond traditional diagnostic boundaries. Our investigation provides support to emerging conceptualisations of psychiatric illness, in which each disorder is best understood as a combination of diagnosis-specific features and a trans-diagnostic factor reflecting general psychopathology. Background: Present pharmacological treatment approaches in schizophrenia rest on "neuroleptic" drugs, all of which act as antagonists at dopamine D2/D3 receptors but additionally display major variability in their binding capacity to neurotransmitter receptors (Van Os & Kapur 2009 ). At present, the choice of any particular drug does not rest on any principled criteria: Once individual treatment has been started, therapeutic efficacy is monitored clinically, and a switch to a different drug is initiated when clear improvements remain absent after a few weeks. It is presently not possible to predict in advance which patients will respond well to a particular drug and who will experience little or no benefit (Case et al. 2011; Kapur et al. 2012) . For instance, clozapine and olanzapine are often prescribed after other antipsychotics have shown to be ineffective in patients with schizophrenia or related disorders due to their pronounced side-effects. Both drugs, clozapine and olanzapine, share certain pharmacodynamic properties with comparatively low affinity towards dopamine D2-receptors, but very high affinity towards muscarinic receptors -a unique constellation that distinguishes them from other common antipsychotics. Importantly, previous studies have shown that a subgroup of schizophrenia patients might particularly benefit from these properties (Raedler et al. 2003 , Scarr et al. 2009 ).
S23. INTRODUCING COMPASS: COMPARING BRAIN ACTIVITY ACROSS PATIENTS WITH
Here, we present an ongoing observational study (COMPASS) which builds on these observations and addresses the question whether functional readouts of dopaminergic and muscarinic systems in individual patients could enable personalised treatment predictions. Guided by the dysconnection hypothesis of schizophrenia (Stephan et al., 2009) , which postulates aberrant interactions between NMDA receptors and neuromodulators like dopamine/acetylcholine, the COMPASS study adopts a neuromodeling approach. The focus is on EEG/fMRI paradigms and computational models with empirically demonstrated sensitivity for altered function of NMDA, dopamine and muscarinic receptors, respectively. Methods: To detect even small effect sizes, the study aims to recruit N=120 patients with schizophrenia who begin treatment with, switch to, or augment medication with olanzapine or clozapine. If possible, a replication sample (an additional N=120) will be recruited, too. Patients will be examined +/-96h relative to treatment onset. Data acquisition encompasses the following measurements: Clinical interview, EEG (working memory, reward learning under volatility, auditory MMN under volatility, "resting"-state), MRI (optional; fMRI during auditory MMN under volatility, "resting"-state, and structural imaging), blood samples (genetic and biochemical analyses). After 2 and 8 weeks a clinical follow-up is conducted. Results: The study is ongoing. Discussion: The EEG/fMRI data will be analysed by computational models that infer functional states of glutamatergic, dopaminergic, and cholinergic systems (for review, Stephan et al. 2015) . Model parameter estimates will serve as features in machine learning analyses of treatment prediction (Brodersen et al. 2014) . If successful, this proof-of-concept study will lead to clinically useful tests for predicting the efficacy of clozapine/olanzapine prior to or during very early treatment. This could have a significant impact on clinical management as it would enable predicting, at an early stage, the therapeutic benefit for individual patients. Our neuromodeling approach to individual predictions may thus provide a principled basis for treatment decisions, help spare side-effects and enable informed switches in treatment strategy.
